rezafungin

Rezafungin is a next-generation, semi-synthetic echinocandin antifungal drug indicated for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options. It acts by inhibiting the fungal-specific enzyme 1,3-beta-D-glucan synthase, which is essential for fungal cell wall synthesis. This inhibition leads to decreased synthesis of beta(1,3)-D-glucan, weakening the fungal cell wall and resulting in osmotic lysis and cell death. Rezafungin is notable for its long half-life (over 130 hours), allowing once-weekly intravenous dosing. It demonstrates activity against various Candida species (including C. albicans, C. glabrata, C. parapsilosis, and C. tropicalis) as well as Aspergillus species[3][5][6]. Clinical studies have shown it to be non-inferior to caspofungin for these indications.

Brand names

Rezzayo

Other names

rezafungin [USAN]